Description
(AWP Alliance News) - DocMorris raised its 2026 external revenue growth forecast to 12.5%-15% from 9%-13%. It now expects adjusted EBITDA better than a CHF 10 million loss, versus a previous loss forecast of CHF 10 million to CHF 17.5 million.
The upgrade follows third-quarter adjusted EBITDA of CHF 600,000, reaching breakeven ahead of schedule. Third-quarter external revenue rose 21.5% in local currency to CHF 342.7 million, driven by prescription medicine growth of 78.3%.
Capital expenditure guidance remains below CHF 30 million, with free cash flow breakeven still targeted during 2027.
https://www.publicnow.com/view/34D80B42DB6BA265A7C042E61283BF0D2CB6F809…
Disclaimer: This news brief was created using generative artificial intelligence. DocMorris AG published the original content used to generate this news brief via EQS News on October 15, 2026, and is solely responsible for the information contained therein.
